NASDAQ$SKIN
SkinHealth Systems Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
BeautyHealth delivered strong growth, driven by robust demand and the successful launch of Syndeo, leading to increased full-year guidance.
BeautyHealth reported a strong first quarter with net sales increasing by 58.6% to $75.4 million. The company raised its full-year net sales guidance to $330-340 million, reflecting confidence in its growth plan.
- Net sales increased by 58.6% to $75.4 million compared to Q1 2021.
- Delivery Systems net sales increased to $41.6 million, driven by the successful launch of Syndeo.
- Consumables net sales increased to $33.8 million, reflecting continued strong demand.
- The company increased its full-year net sales guidance to $330.0 million - $340.0 million.
Headline financials
Revenue & EPS history
Beauty Health · Revenue · Quarterly
$75.4M
Revenue by segment
Beauty Health · $75.4M total across 2 segments · Q1 2022
- Delivery Systems$41.6M+62.5%55.2%
- Consumables$33.8M+54.3%44.8%
Forward guidance
BeautyHealth increased its fiscal 2022 guidance and now expects net sales in the range of $330.0 million to $340.0 million, up from the previous outlook for $320.0 million to $330.0 million. The Company also reaffirmed its outlook for adjusted EBITDA of approximately $50.0 million.
Tailwinds
- Increased full-year net sales guidance to $330.0 million - $340.0 million.
- Reaffirmed outlook for adjusted EBITDA of approximately $50.0 million.
- Reflects management's confidence in the business.
- Company executes against its growth plan.
- Momentum in health and wellness.
Headwinds
- Assumes no material deterioration in general market conditions.
- Assumes no material deterioration or other factors related to COVID-19 trends.
- Cautious of the potential risk for further market closures or other restrictive measures from existing or new COVID-19 strains.
- Uneven global rollout and adoption of vaccines.
- Inflationary headwinds related to higher raw material, shipping and labor costs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
+0.6%
Avg return
Earnings day
-0.5%
Avg return
5 days after
-1.9%
Avg return
30 days after
52%
12 / 23 earnings
Positive
+52.1%
Q1 2025
Best reaction
-61.4%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.5% | -29.9% | -34.9% | |
| Q4 2025 | +19.8% | +11.3% | -15.3% | |
| Q3 2025 | +8.7% | +3.1% | +13.2% | |
| Q1 2025 | +52.1% | +19.4% | +29.0% | |
| Q4 2024 | -5.6% | -9.9% | -26.1% | |
| Q3 2024 | +5.1% | -13.1% | -14.2% | |
| Q2 2024 | -10.4% | +0.8% | +12.8% | |
| Q1 2024 | -20.1% | -18.4% | -39.9% | |
| Q4 2023 | +16.8% | -0.8% | +4.4% | |
| Q3 2023 | -61.4% | -37.2% | -14.7% | |
| Q2 2023 | -6.0% | -12.9% | -24.2% | |
| Q1 2023 | -2.8% | -0.2% | -20.8% | |
| Q4 2022 | +8.7% | +13.5% | +7.4% | |
| Q3 2022 | -25.3% | -12.3% | -4.1% | |
| Q2 2022 | -8.3% | -8.8% | -18.5% | |
| Q1 2022 | -5.4% | +6.6% | +8.9% | |
| Q4 2019 | +4.0% | -4.1% | -12.9% | |
| Q4 2021 | +23.4% | +43.1% | +27.6% | |
| Q3 2021 | -11.9% | -8.0% | -13.9% | |
| Q2 2020 | +8.2% | +7.4% | +26.8% | |
| Q2 2021 | +10.6% | +23.9% | +30.3% | |
| Q1 2021 | +12.8% | +15.9% | +44.7% | |
| Q4 2020 | +2.8% | -0.9% | -10.0% | |
| Q3 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro